VTAE Depositi SEC - Vitae Pharmaceuticals, Inc.- Relazione annuale, dichiarazione di delega, prospetto informativo

Statistiche di base

CIK

1157602

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Vitae Pharmaceuticals, Inc.

SEC Filings (Chronological Order)

Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.

February 14, 2017	EX-99	JOINT FILING AGREEMENT EX-99 2 exhibit99.htm Exhibit 1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of February 14, 2017, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Asset Management, LLC and Bihua Chen (collectively, the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a stateme
February 14, 2017	SC 13G/A	VTAE / Vitae Pharmaceuticals, Inc. / Biotechnology Value Fund L P - AMENDMENT NO. 3 TO THE SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)1 Vitae Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $.0001 par value per share (Title of Class of Securities) 92847N 10 3 (CUSIP Nu
February 14, 2017	SC 13G/A	VTAE / Vitae Pharmaceuticals, Inc. / Cormorant Asset Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Vitae Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92847N103 (CUSIP Number) December 31, 2016 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designat
November 4, 2016	15-12B	Vitae Pharmaceuticals 15-12B 15-12B 1 a16-2102011512b.htm 15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-36617 Vitae Pharmaceuticals, Inc. (E
October 25, 2016	S-8 POS	Vitae Pharmaceuticals S-8 POS As filed with the Securities and Exchange Commission on October 25, 2016 Registration No.
October 25, 2016	S-8 POS	Vitae Pharmaceuticals S-8 POS As filed with the Securities and Exchange Commission on October 25, 2016 Registration No.
October 25, 2016	S-8 POS	Vitae Pharmaceuticals S-8 POS As filed with the Securities and Exchange Commission on October 25, 2016 Registration No.
October 25, 2016	POS AM	Vitae Pharmaceuticals POS AM As filed with the Securities and Exchange Commission on October 25, 2016. Registration No. 333-207290 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VITAE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of inc
October 25, 2016	EX-3.1	AMENDED AND RESTATED CERTIFICATE OF INCORPORATION VITAE PHARMACEUTICALS, INC. EX-3.1 2 a16-202832ex3d1.htm EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF VITAE PHARMACEUTICALS, INC. FIRST: The name of the Corporation is Vitae Pharmaceuticals, Inc. SECOND: The Corporation’s registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street, in the City of Wilmington, County of New Castle, State of Delaware 19801. The name of i
October 25, 2016	8-K	Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Termination of a Material Definitive Agreement, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2016 VITAE PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36617 (Commission File
October 25, 2016	EX-3.2	VITAE PHARMACEUTICALS, INC. AMENDED AND RESTATED BYLAWS As Adopted on October 25, 2016 Exhibit 3.2 VITAE PHARMACEUTICALS, INC. AMENDED AND RESTATED BYLAWS As Adopted on October 25, 2016 VITAE PHARMACEUTICALS, INC. AMENDED AND RESTATED BYLAWS Table of Contents Page ARTICLE I MEETINGS OF STOCKHOLDERS 1 Section 1.01. Annual Meetings 1 Section 1.02. Special Meetings 1 Section 1.03. Participation in Meetings by Remote Communication 1 Section 1.04. Notice of Meetings; Waiver of Notice 1 S
October 25, 2016	SC 14D9/A	Vitae Pharmaceuticals SC 14D9/A SC 14D9/A 1 a16-202831sc14d9a.htm SC 14D9/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 3) Vitae Pharmaceuticals, Inc. (Name of Subject Company) Vitae Pharmaceuticals, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.0001 p
October 25, 2016	EX-99.(A)(1)(L)	Allergan Successfully Completes Vitae Tender Offer – Acquisition Adds Differentiated Development Programs to Strengthen Allergan’s Medical Dermatology Pipeline – – Vitae’s Contour Drug Discovery Platform and Team Bolsters Allergan’s Discovery Researc EX-99.(A)(1)(L) 2 d231990dex99a1l.htm EX-99.(A)(1)(L) Exhibit (a)(1)(L) CONTACTS: ALLERGAN: Investors: Lisa DeFrancesco (862) 261-7152 Media: Mark Marmur (862) 261-7558 Allergan Successfully Completes Vitae Tender Offer – Acquisition Adds Differentiated Development Programs to Strengthen Allergan’s Medical Dermatology Pipeline – – Vitae’s Contour Drug Discovery Platform and Team Bolsters Allergan’
October 25, 2016	SC TO-T/A	Vitae Pharmaceuticals SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (RULE 14D-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) VITAE PHARMACEUTICALS, INC. (Name of Subject Company) AUGUSTA MERGER SUB, INC. (Offeror) A Wholly Owned Subsidiary of ALLERGAN HOLDCO US, INC. (Parent of Offeror) An Indi
October 17, 2016	SC 14D9/A	Vitae Pharmaceuticals SC 14D9/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) Vitae Pharmaceuticals, Inc. (Name of Subject Company) Vitae Pharmaceuticals, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 9284
October 17, 2016	EX-99.(A)(1)(K)	Allergan and Vitae Pharmaceuticals Announce Expiration of HSR Waiting Period for Allergan’s Proposed Acquisition of Vitae EX-99.(a)(1)(K) Exhibit (a)(1)(K) NEWS RELEASE CONTACTS: ALLERGAN: Investors: Lisa DeFrancesco (862) 261-7152 Media: Mark Marmur (862) 261-7558 Vitae: Investors: Richard S. Morris Chief Financial Officer (215) 461-2000 Westwicke Partners John Woolford (443) 213-0506 Media: 6 Degrees PR Tony Plohoros (908) 591-2839 Allergan and Vitae Pharmaceuticals Announce Expiration of HSR Waiting Period for All
October 17, 2016	SC TO-T/A	Vitae Pharmaceuticals SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (RULE 14D-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) VITAE PHARMACEUTICALS, INC. (Name of Subject Company) AUGUSTA MERGER SUB, INC. (Offeror) A Wholly Owned Subsidiary of ALLERGAN HOLDCO US, INC. (Parent of Offeror) An Indi
October 4, 2016	SC 14D9/A	Vitae Pharmaceuticals SC 14D9/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) Vitae Pharmaceuticals, Inc. (Name of Subject Company) Vitae Pharmaceuticals, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 9284
October 4, 2016	SC TO-T/A	Vitae Pharmaceuticals SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (RULE 14D-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) VITAE PHARMACEUTICALS, INC. (Name of Subject Company) AUGUSTA MERGER SUB, INC. (Offeror) A Wholly Owned Subsidiary of ALLERGAN HOLDCO US, INC. (Parent of Offeror) An Indi
September 26, 2016	EX-99.(E)(5)(F)	EMPLOYMENT AGREEMENT EX-99.(E)(5)(F) 2 a2229819zex-99e5f.htm EX-99.(E)(5)(F) Exhibit (e)(5)(F) EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT (“Agreement”) dated as of August 10, 2016, by and between Vitae Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Scott Applebaum (the “Executive”). WHEREAS, the Company wishes to continue to employ the Executive to serve as the Company’s General Counsel and Corporat
September 26, 2016	SC 14D9	Vitae Pharmaceuticals SC 14D9 QuickLinks - Click here to rapidly navigate through this document SECURITIES AND EXCHANGE COMMISSION Washington, D.
September 26, 2016	EX-99.(A)(1)(E)	Offer To Purchase For Cash All Outstanding Shares of Common Stock VITAE PHARMACEUTICALS, INC. a Delaware corporation $21.00 net per share Pursuant to the Offer to Purchase dated September 26, 2016 AUGUSTA MERGER SUB, INC. a wholly owned subsidiary of EX-99.(a)(1)(E) Exhibit (a)(1)(E) Offer To Purchase For Cash All Outstanding Shares of Common Stock of VITAE PHARMACEUTICALS, INC. a Delaware corporation at $21.00 net per share Pursuant to the Offer to Purchase dated September 26, 2016 by AUGUSTA MERGER SUB, INC. a wholly owned subsidiary of ALLERGAN HOLDCO US, INC. and an indirect wholly owned subsidiary of ALLERGAN plc THE OFFER AND WITHDRAWAL
September 26, 2016	EX-99.(A)(1)(D)	Offer To Purchase For Cash All Outstanding Shares of Common Stock VITAE PHARMACEUTICALS, INC. a Delaware corporation $21.00 net per share Pursuant to the Offer to Purchase dated September 26, 2016 AUGUSTA MERGER SUB, INC. a wholly owned subsidiary of EX-99.(a)(1)(D) Exhibit (a)(1)(D) Offer To Purchase For Cash All Outstanding Shares of Common Stock of VITAE PHARMACEUTICALS, INC. a Delaware corporation at $21.00 net per share Pursuant to the Offer to Purchase dated September 26, 2016 by AUGUSTA MERGER SUB, INC. a wholly owned subsidiary of ALLERGAN HOLDCO US, INC. and an indirect wholly owned subsidiary of ALLERGAN plc THE OFFER AND WITHDRAWAL
September 26, 2016	EX-99.(A)(1)(A)	Offer to Purchase for Cash All Outstanding Shares of Common Stock VITAE PHARMACEUTICALS, INC. a Delaware corporation $21.00 net per share AUGUSTA MERGER SUB, INC. a wholly owned subsidiary of ALLERGAN HOLDCO US, INC. and an indirect wholly owned subs EX-99.(a)(1)(A) Table of Contents Exhibit (a)(1)(A) Offer to Purchase for Cash All Outstanding Shares of Common Stock of VITAE PHARMACEUTICALS, INC. a Delaware corporation at $21.00 net per share by AUGUSTA MERGER SUB, INC. a wholly owned subsidiary of ALLERGAN HOLDCO US, INC. and an indirect wholly owned subsidiary of ALLERGAN plc THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT THE END OF THE DAY,
September 26, 2016	SC TO-T	Vitae Pharmaceuticals SC TO-T SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (RULE 14D-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 VITAE PHARMACEUTICALS, INC. (Name of Subject Company) AUGUSTA MERGER SUB, INC. (Offeror) A Wholly Owned Subsidiary of ALLERGAN HOLDCO US, INC. (Parent of Offeror) An Indirect Wholly Owned Su
September 26, 2016	EX-99.(A)(1)(C)	NOTICE OF GUARANTEED DELIVERY For Tender of Shares of Common Stock VITAE PHARMACEUTICALS, INC. a Delaware corporation $21.00 net per share Pursuant to the Offer to Purchase Dated September 26, 2016 AUGUSTA MERGER SUB, INC. a wholly owned subsidiary o EX-99.(a)(1)(C) Exhibit (a)(1)(C) NOTICE OF GUARANTEED DELIVERY For Tender of Shares of Common Stock of VITAE PHARMACEUTICALS, INC. a Delaware corporation at $21.00 net per share Pursuant to the Offer to Purchase Dated September 26, 2016 by AUGUSTA MERGER SUB, INC. a wholly owned subsidiary of ALLERGAN HOLDCO US, INC. and an indirect wholly owned subsidiary of ALLERGAN plc THE OFFER AND WITHDRAWAL
September 26, 2016	EX-99.(A)(1)(B)	LETTER OF TRANSMITTAL To Tender Shares of Common Stock VITAE PHARMACEUTICALS, INC. a Delaware corporation $21.00 net per share Pursuant to the Offer to Purchase dated September 26, 2016 AUGUSTA MERGER SUB, INC. a wholly owned subsidiary of ALLERGAN H EX-99.(a)(1)(B) Exhibit (a)(1)(B) LETTER OF TRANSMITTAL To Tender Shares of Common Stock of VITAE PHARMACEUTICALS, INC. a Delaware corporation at $21.00 net per share Pursuant to the Offer to Purchase dated September 26, 2016 by AUGUSTA MERGER SUB, INC. a wholly owned subsidiary of ALLERGAN HOLDCO US, INC. and an indirect wholly owned subsidiary of ALLERGAN plc THE OFFER AND WITHDRAWAL RIGHTS WILL
September 26, 2016	EX-99.(D)(2)	CONFIDENTIALITY AGREEMENT EX-99.(d)(2) Exhibit (d)(2) CONFIDENTIALITY AGREEMENT This CONFIDENTIALITY AGREEMENT (?Agreement?) is being entered into as of August 17, 2016 between Vitae Pharmaceuticals, Inc., a Delaware corporation (?Vitae?), and Allergan, Inc., a Delaware corporation (?Allergan? and with Vitae referred to collectively as the ?Parties? and individually as a ?Party?). In order to facilitate the consideration a
September 26, 2016	EX-99.(A)(1)(J)	Notice of Offer to Purchase for Cash All Outstanding Shares of Common Stock VITAE PHARMACEUTICALS, INC. a Delaware corporation $21.00 net per share Pursuant to the Offer to Purchase dated September 26, 2016 AUGUSTA MERGER SUB, INC. a wholly owned sub EX-99.(a)(1)(J) Exhibit (a)(1)(J) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below), and the provisions herein are subject in their entirety to the provisions of the Offer (as defined below). The Offer is made solely by the Offer to Purchase, dated September 26, 2016, and the related Letter of Transmittal and any amendments or supple
September 21, 2016	SC TO-C	Vitae Pharmaceuticals SC TO-C SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (RULE 14D-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 VITAE PHARMACEUTICALS, INC. (Name of Subject Company) AUGUSTA MERGER SUB, INC. (Offeror) A Wholly Owned Subsidiary of ALLERGAN HOLDCO US, INC. (Parent of Offeror) An Indirect Wholly Owned Su
September 21, 2016	EX-99.1	ALLERGAN THERAPEUTICS TO ACQUIRE AND ACQUIRES TOBIRA AKARNA THERAPEUTICS EX-99.1 Exhibit 99.1 ALLERGAN THERAPEUTICS TO ACQUIRE AND ACQUIRES TOBIRA AKARNA THERAPEUTICS ALLERGAN PHARMACEUTICALS TO ACQUIRE VITAE Taking a Leading R&D Position in NASH and Expanding Global Dermatology Pipeline ALLERGAN CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This presentation contains ?forward-looking statements? relating to the acquisitions of Tobira Therapeutics, Inc. (?T
September 16, 2016	SC 13G/A	VTAE / Vitae Pharmaceuticals, Inc. / Adage Capital Partners GP LLC - VITAE PHARMACEUTICALS, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Vitae Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92847N103 (CUSIP Number) September 14, 2016 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule
September 14, 2016	SC14D9C	Vitae Pharmaceuticals SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 VITAE PHARMACEUTICALS, INC. (Name of Subject Company) VITAE PHARMACEUTICALS, INC. (Name of Person Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92847N103 (CUSIP Number
September 14, 2016	SC TO-C	Vitae Pharmaceuticals FORM 8-K SC TO-C 1 d259988d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 14, 2016 (September 14, 2016) ALLERGAN PLC (Exact name of registrant as specified in its charter) Ireland (State or other jurisdiction of i
September 14, 2016	EX-99.2	Today, we are announcing plans to acquire Vitae Pharmaceuticals, a biotech company with a strong pipeline of dermatology treatments. This is the latest ‘Stepping Stone’ deal that leverages our Open Science model to further expand our R&D pipeline and EX-99.2 Exhibit 99.2 Date: September 14, 2016 To: All Colleagues From: Bill Meury, Chief Commercial Officer and David Nicholson, Chief R&D Officer RE: Allergan to Acquire Vitae Pharmaceuticals Adding Innovative R&D Programs for Dermatology Today, we are announcing plans to acquire Vitae Pharmaceuticals, a biotech company with a strong pipeline of dermatology treatments. This is the latest ?Steppin
September 14, 2016	EX-99.3	ALLERGAN TO ACQUIRE VITAE PHARMACEUTICALS EX-99.3 Exhibit 99.3 ALLERGAN TO ACQUIRE VITAE PHARMACEUTICALS Strengthening Allergan?s Medical Dermatology Pipeline ALLERGAN CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This presentation contains ?forward-looking statements? relating to the acquisition of Vitae by Allergan. Such forward-looking statements include the ability of Vitae, Parent and Merger Sub to complete the transactio
September 14, 2016	EX-99.1	Allergan to Acquire Vitae Pharmaceuticals Adding Innovative Development Programs for Dermatologic Conditions – Acquisition Adds Differentiated Development Programs to Strengthen Allergan’s Medical Dermatology Pipeline – – VTP-43742, First-in-Class Or EX-99.1 Exhibit 99.1 NEWS RELEASE CONTACTS: ALLERGAN: Investors: Lisa DeFrancesco (862) 261-7152 Media: Mark Marmur (862) 261-7558 VITAE: Investors: Richard S. Morris Chief Financial Officer (215) 461-2000 Westwicke Partners John Woolford (443) 213-0506 Media: 6 Degrees PR Tony Plohoros (908) 591-2839 Allergan to Acquire Vitae Pharmaceuticals Adding Innovative Development Programs for Dermatologic
September 14, 2016	EX-2.1	AGREEMENT AND PLAN OF MERGER dated as of September 13, 2016, ALLERGAN HOLDCO US, INC., AUGUSTA MERGER SUB, INC. VITAE PHARMACEUTICALS, INC. EX-2.1 2 a16-185041ex2d1.htm EX-2.1 Exhibit 2.1 CONFIDENTIAL EXECUTION VERSION AGREEMENT AND PLAN OF MERGER dated as of September 13, 2016, among ALLERGAN HOLDCO US, INC., AUGUSTA MERGER SUB, INC. and VITAE PHARMACEUTICALS, INC. TABLE OF CONTENTS Page ARTICLE I THE OFFER Section 1.01 The Offer 2 Section 1.02 Company Actions 5 ARTICLE II THE MERGER Section 2.01 The Merger 6 Section 2.02 Merger Clos
September 14, 2016	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 a16-1850418k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2016 VITAE PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36617 04-3567753 (State or Other Jurisdic
September 14, 2016	EX-99.1	Allergan to Acquire Vitae Pharmaceuticals Adding Innovative Development Programs for Dermatologic Conditions — Acquisition Adds Differentiated Development Programs to Strengthen Allergan’s Medical Dermatology Pipeline — — VTP-43742, First-in-Class Or Exhibit 99.1 NEWS RELEASE CONTACTS: ALLERGAN: Investors: Lisa DeFrancesco (862) 261-7152 Media: Mark Marmur (862) 261-7558 Vitae: Investors: Richard S. Morris Chief Financial Officer (215) 461-2000 Westwicke Partners John Woolford (443) 213-0506 Media: 6 Degrees PR Tony Plohoros (908) 591-2839 Allergan to Acquire Vitae Pharmaceuticals Adding Innovative Development Programs for Dermatologic Conditi
August 15, 2016	SC 13G	VTAE / Vitae Pharmaceuticals, Inc. / RA Capital Management, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Vitae Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92847N103 (CUSIP Number) August 5, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th
August 15, 2016	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 v447005ex99-1.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of August 15, 2016, is by and among RA Capital Management, LLC, Peter Kolchinsky, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange
August 15, 2016	SC 13G	VTAE / Vitae Pharmaceuticals, Inc. / RA Capital Management, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Vitae Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92847N103 (CUSIP Number) August 5, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th
August 15, 2016	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 v447005ex99-1.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of August 15, 2016, is by and among RA Capital Management, LLC, Peter Kolchinsky, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange
August 4, 2016	10-Q	Vitae Pharmaceuticals 10-Q (Quarterly Report) vtaeCurrentFolio10Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 4, 2016	EX-10.37	EMPLOYMENT AGREEMENT Exhibit 10.37 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT (“Agreement”) dated as of August 3, 2016, by and between Vitae Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Richard Morris (the “Executive”). WHEREAS, the Company wishes to continue to employ the Executive to serve as the Company’s Chief Financial Officer, and the Executive is willing to continue to be employed and to se
August 4, 2016	EX-10.33	Vitae Pharmaceuticals, Inc. Management Cash Incentive Plan (As Amended and restated Effective June 28, 2016) Exhibit 10.33 Vitae Pharmaceuticals, Inc. Management Cash Incentive Plan (As Amended and restated Effective June 28, 2016) TABLE OF CONTENTS Page ARTICLE 1. BACKGROUND AND PURPOSE 1 1.1 Effective Date 1 1.2 Purpose of the Plan 1 ARTICLE 2. DEFINITIONS 1 ARTICLE 3. SELECTION OF PARTICIPANTS AND DETERMINATION OF AWARDS 3 3.1 Selection of Participants 3 3.2 Determination of Performance Goals 3 3.3 De
August 4, 2016	EX-10.38	EMPLOYMENT AGREEMENT Exhibit 10.38 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT (“Agreement”) dated as of August 3, 2016, by and between Vitae Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Carole Sable, M.D. (the “Executive”). WHEREAS, the Company wishes to continue to employ the Executive to serve as the Company’s Chief Medical Officer, and the Executive is willing to continue to be employed and to
August 4, 2016	EX-10.35	EMPLOYMENT AGREEMENT Exhibit 10.35 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT (“Agreement”) dated as of August 3, 2016, by and between Vitae Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Richard Gregg, M.D. (the “Executive”). WHEREAS, the Company wishes to continue to employ the Executive to serve as the Company’s Chief Science Officer, and the Executive is willing to continue to be employed and to
August 4, 2016	EX-10.34	EMPLOYMENT AGREEMENT Exhibit 10.34 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT (“Agreement”) dated as of August 3, 2016, by and between Vitae Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Jeffrey Hatfield (the “Executive”). WHEREAS, the Company wishes to continue to employ the Executive to serve as the Company’s Chief Executive Officer and President, and the Executive is willing to continue to be em
August 4, 2016	EX-10.36	EMPLOYMENT AGREEMENT Exhibit 10.36 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT (“Agreement”) dated as of August 3, 2016, by and between Vitae Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Arthur Fratamico, R.Ph. (the “Executive”). WHEREAS, the Company wishes to continue to employ the Executive to serve as the Company’s Chief Business Officer, and the Executive is willing to continue to be employed a
August 3, 2016	EX-99.2	Second Quarter 2016 Earnings Call August 3, 2016 Exhibit 99.2 Second Quarter 2016 Earnings Call August 3, 2016 Disclaimer Regarding Forward Looking Statements This presentation includes statements that are, or may be deemed, "forward-looking statements", within the meaning of Section 27A of the Securities Act of 1933, as amended. All statements, other than statements of historical facts, included in this presentation regarding our strategy, futu
August 3, 2016	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a16-1603918k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2016 VITAE PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 00
August 3, 2016	EX-99.1	Vitae Pharmaceuticals Reports Second Quarter 2016 Operating and Financial Results Proof-of-concept data for VTP-38543 expected in the fourth quarter of 2016 Conference call scheduled for 4:30 p.m. EDT today EX-99.1 2 a16-160391ex99d1.htm EX-99.1 Exhibit 99.1 Vitae Pharmaceuticals Reports Second Quarter 2016 Operating and Financial Results Proof-of-concept data for VTP-38543 expected in the fourth quarter of 2016 Conference call scheduled for 4:30 p.m. EDT today FORT WASHINGTON, PA, August 3, 2016 — Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE), a clinical-stage biotechnology company, today reported its
July 27, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits 8-K 1 a16-1555718k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2016 VITAE PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001
July 27, 2016	EX-99.1	Vitae Pharmaceuticals Appoints Daniel M. Junius to Board of Directors Bryan Roberts, Ph.D. steps down from board EX-99.1 2 a16-155571ex99d1.htm EX-99.1 Exhibit 99.1 Vitae Pharmaceuticals Appoints Daniel M. Junius to Board of Directors Bryan Roberts, Ph.D. steps down from board FORT WASHINGTON, PA, July 27, 2016 — Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE), a clinical-stage biotechnology company, today announced the appointment of Daniel M. Junius to its board of directors, effective immediately. Mr. Junius r
July 27, 2016	EX-24	POWER OF ATTORNEY Exhibit 24 POWER OF ATTORNEY The undersigned individual (the ?Reporting Person?) hereby constitutes and appoints each of Arthur Fratamico and Richard Morris, signing singly, with full power of substitution, as the Reporting Person?s true and lawful attorney in fact to: (1) prepare, execute in the Reporting Person?s name and on the Reporting Person?s behalf, and submit to the U.
June 30, 2016	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2016 VITAE PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36617 (Commission File Num
June 30, 2016	424B5	Up to $40,000,000 Common Stock Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed pursuant to Rule 424(b)(5) Registration No.
June 30, 2016	EX-10.32	VITAE PHARMACEUTICALS, INC. Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales Agreement EX-10.32 3 a16-142321ex10d32.htm EX-10.32 Exhibit 10.32 VITAE PHARMACEUTICALS, INC. Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales Agreement June 30, 2016 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Vitae Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor
May 26, 2016	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2016 VITAE PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36617 (Commission File Numb
May 10, 2016	10-Q	Vitae Pharmaceuticals 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36617 VITAE PHARMACEUTICALS, INC
May 10, 2016	EX-99.1	Vitae Pharmaceuticals Reports First Quarter 2016 Operating and Financial Results Proof-of-concept data for VTP-38543 expected in the second half of 2016 Conference call scheduled for 4:30 p.m. EDT today Exhibit 99.1 Vitae Pharmaceuticals Reports First Quarter 2016 Operating and Financial Results Proof-of-concept data for VTP-38543 expected in the second half of 2016 Conference call scheduled for 4:30 p.m. EDT today FORT WASHINGTON, PA, May 10, 2016 ? Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE), a clinical-stage biotechnology company, today reported its operating and financial results for the quart
May 10, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2016 VITAE PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36617 (Commission File Numb
April 13, 2016	DEFA14A	Vitae Pharmaceuticals DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin
April 13, 2016	DEF 14A	Vitae Pharmaceuticals DEF 14A DEF 14A 1 a2228196zdef14a.htm DEF 14A Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box
March 28, 2016	SC 13G/A	VTAE / Vitae Pharmaceuticals, Inc. / Adage Capital Partners GP LLC - VITAE PHARMACEUTICALS, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Vitae Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92847N103 (CUSIP Number) March 24, 2016 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule purs
March 25, 2016	424B5	VITAE PHARMACEUTICALS, INC. Common Stock $6.00 per share Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS 2 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No.
March 24, 2016	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2016 VITAE PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36617 04-3567753 (State or Other Jurisdiction of Incorporation) (Commiss
March 24, 2016	EX-99.1	Vitae Pharmaceuticals Prices Public Offering of Common Stock EX-99.1 4 a16-71431ex99d1.htm EX-99.1 Exhibit 99.1 Vitae Pharmaceuticals Prices Public Offering of Common Stock FORT WASHINGTON, PA, March 24, 2016 — Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE), a clinical-stage biotechnology company, today announced the pricing of an underwritten public offering of 5,833,333 shares of its common stock at a price to the public of $6.00 per share. In connection with
March 24, 2016	EX-1.1	5,833,333 Shares Vitae Pharmaceuticals, Inc. Common Stock UNDERWRITING AGREEMENT Exhibit 1.1 EXECUTION VERSION 5,833,333 Shares Vitae Pharmaceuticals, Inc. Common Stock UNDERWRITING AGREEMENT March 24, 2016 PIPER JAFFRAY & CO. BMO CAPITAL MARKETS CORP. As representatives of the several Underwriters named in Schedule I hereto c/o Piper Jaffray & Co. 800 Nicollet Mall Minneapolis, Minnesota 55402 and c/o BMO Capital Markets Corp. 3 Times Square New York, New York 10036 Ladies an
March 23, 2016	EX-99.1	Vitae Pharmaceuticals Proposes Public Offering of Common Stock EX-99.1 2 a16-70991ex99d1.htm EX-99.1 Exhibit 99.1 Vitae Pharmaceuticals Proposes Public Offering of Common Stock FORT WASHINGTON, PA, March 23, 2016 — Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE) (Vitae), a clinical-stage biotechnology company, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares in the offering are to be
March 23, 2016	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2016 VITAE PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36617 (Commission File Nu
March 23, 2016	424B5	Subject To Completion, Dated March 23, 2016 Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS 2 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No.
March 17, 2016	EX-1	JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of March 17, 2016, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Asset Management, LLC and Bihua Chen (collectively, the “Filers”).
March 17, 2016	SC 13G	VTAE / Vitae Pharmaceuticals, Inc. / Cormorant Global Healthcare Master Fund, LP Passive Investment SC 13G 1 sch13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Vitae Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92847N103 (CUSIP Number) March 11, 2016 (Date of Event which Requires Filing of this Statement) Check the appropriate
March 16, 2016	EX-99.1	VTP-43742: First-in-Class RORt Inhibitor Ph 2a Proof-of-Concept Results in Psoriasis March 16, 2016 EX-99.1 2 a16-66951ex99d1.htm EX-99.1 Exhibit 99.1 VTP-43742: First-in-Class RORt Inhibitor Ph 2a Proof-of-Concept Results in Psoriasis March 16, 2016 Disclaimer Regarding Forward Looking Statements This presentation includes statements that are, or may be deemed, “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended. All statements, other than s
March 16, 2016	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events 8-K 1 a16-669518k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2016 VITAE PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36617 04-3567753 (State or other jurisdiction
March 16, 2016	EX-99.2	Vitae Pharmaceuticals Achieves Proof-of-Concept with First-in-Class RORγt Inhibitor in Moderate to Severe Psoriasis VTP-43742 demonstrated statistically significant efficacy and was well tolerated Company plans to move VTP-43742 forward into 16-week EX-99.2 3 a16-66951ex99d2.htm EX-99.2 Exhibit 99.2 Vitae Pharmaceuticals Achieves Proof-of-Concept with First-in-Class RORγt Inhibitor in Moderate to Severe Psoriasis VTP-43742 demonstrated statistically significant efficacy and was well tolerated Company plans to move VTP-43742 forward into 16-week study Conference call to discuss results at 5:00 p.m. ET, March 16, 2016 James Krueger, M.D., Ph.D.
March 4, 2016	S-8	Vitae Pharmaceuticals S-8 As filed with the Securities and Exchange Commission on March 4, 2016 Registration No.
March 4, 2016	10-K	Vitae Pharmaceuticals 10-K (Annual Report) Use these links to rapidly review the document TABLE OF CONTENTS Vitae Pharmaceuticals, Inc.
March 3, 2016	EX-99.1	Vitae Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Operating and Financial Results Proof-of-concept data for VTP-43742 expected in the first quarter of 2016 Initiated proof-of-concept trial of VTP-38543 in patients with atopic dermatitis Exhibit 99.1 Vitae Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Operating and Financial Results Proof-of-concept data for VTP-43742 expected in the first quarter of 2016 Initiated proof-of-concept trial of VTP-38543 in patients with atopic dermatitis Conference call scheduled for 4:30 p.m. EST today FORT WASHINGTON, PA, March 3, 2016 ? Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE), a cli
March 3, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a16-571418k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2016 VITAE PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-
February 16, 2016	EX-99.1	Joint Filing Agreement EX-99.1 2 ex991to13ga207422vit021616.htm JOINT FILING AGREEMENT Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated February 16, 2016 with respect to the shares of Common Stock of Vitae Pharmaceuticals, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursua
February 16, 2016	SC 13G/A	Vitae Pharmaceuticals AMENDMENT NO. 2 TO THE SCHEDULE 13G (Passive Acquisition of More Than 5% of Shares) SC 13G/A 1 sc13ga207422vit02162016.htm AMENDMENT NO. 2 TO THE SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 Vitae Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par
February 16, 2016	SC 13G/A	VTAE / Vitae Pharmaceuticals, Inc. / Adage Capital Partners GP LLC - 16-0356 VITAE PHARMACEUTICALS, INC. Passive Investment SC 13G/A 1 p16-0356sc13ga.htm 16-0356 VITAE PHARMACEUTICALS, INC. 7 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Vitae Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92847N103 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing
February 12, 2016	SC 13G/A	VTAE / Vitae Pharmaceuticals, Inc. / ATLAS VENTURE FUND VI LP - SC 13G/A Passive Investment SC 13G/A 1 a16-42432sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1)* VITAE PHARMACEUTICALS, INC (Name of Issuer) Common stock, $0.001 (Title of Class of Securities) 92847N103 (CUSIP Number) December 31, 2015 (Dat
January 26, 2016	SC 13G/A	VTAE / Vitae Pharmaceuticals, Inc. / PROSPECT VENTURE PARTNERS II LP - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b) AND (c) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 1)* Vitae Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 92847N 10 3 (CUSIP Number) Dec
December 17, 2015	EX-99.1	Vitae Pharmaceuticals Reports Top-Line Results from Remaining Monotherapy Arm of Phase 2 Clinical Trial of BI187004 in Overweight Type 2 Diabetes Patients Exhibit 99.1 Vitae Pharmaceuticals Reports Top-Line Results from Remaining Monotherapy Arm of Phase 2 Clinical Trial of BI187004 in Overweight Type 2 Diabetes Patients FORT WASHINGTON, PA, December 17, 2015 ? Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE), a clinical-stage biotechnology company, today announced top-line clinical efficacy results from the remaining monotherapy arm of Boehringer Ingelhe
December 17, 2015	8-K	Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K 1 a15-2515818k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2015 VITAE PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incorporation)
December 10, 2015	EX-99.1	Vitae Pharmaceuticals Opens Phase 2a Proof-of-Concept Trial of VTP-38543 in Atopic Dermatitis Patients EX-99.1 2 a15-247391ex99d1.htm EX-99.1 Exhibit 99.1 Vitae Pharmaceuticals Opens Phase 2a Proof-of-Concept Trial of VTP-38543 in Atopic Dermatitis Patients FORT WASHINGTON, PA, December 10, 2015 — Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE), a clinical-stage biotechnology company, today announced updated plans to begin clinical development of VTP-38543 with a four-week Phase 2a proof-of-concept tria
December 10, 2015	8-K	Financial Statements and Exhibits, Other Events 8-K 1 a15-2473918k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2015 VITAE PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incorporation)
November 19, 2015	EX-99.1	Analyst and Investor Briefing November 19, 2015 EX-99.1 2 a15-236372ex99d1.htm EX-99.1 Exhibit 99.1 Analyst and Investor Briefing November 19, 2015 Disclaimer Regarding Forward Looking Statements This presentation includes statements that are, or may be deemed, “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended. All statements, other than statements of historical facts, included in this pre
November 19, 2015	8-K	Vitae Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2015 VITAE PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36617 (Commission File
November 18, 2015	EX-99.1	Vitae Pharmaceuticals Announces Positive Top-Line Results from a Phase 1 Multiple Ascending Dose Trial of VTP-43742 · Multiple ascending doses of VTP-43742 shown to be safe and generally well tolerated in healthy human volunteers · Robust ex vivo bio EX-99.1 2 a15-236371ex99d1.htm EX-99.1 Exhibit 99.1 Vitae Pharmaceuticals Announces Positive Top-Line Results from a Phase 1 Multiple Ascending Dose Trial of VTP-43742 · Multiple ascending doses of VTP-43742 shown to be safe and generally well tolerated in healthy human volunteers · Robust ex vivo biomarker response, suppressing secretion of pro-inflammatory IL-17A by more than 90 percent · Top-li
November 18, 2015	8-K	Financial Statements and Exhibits, Other Events 8-K 1 a15-2363718k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2015 VITAE PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation)
November 6, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 a15-17791110q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 00
November 5, 2015	EX-99.1	Vitae Pharmaceuticals Reports Third Quarter 2015 Operating and Financial Results Announces psoriasis as lead indication for VTP-43742 Conference call scheduled for 4:30 p.m. EST today EX-99.1 2 a15-223871ex99d1.htm EX-99.1 Exhibit 99.1 Vitae Pharmaceuticals Reports Third Quarter 2015 Operating and Financial Results Announces psoriasis as lead indication for VTP-43742 Conference call scheduled for 4:30 p.m. EST today FORT WASHINGTON, PA, November 5, 2015 — Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE), a clinical-stage biotechnology company developing a robust and growing portfolio
November 5, 2015	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a15-2238718k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2015 VITAE PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation)
November 4, 2015	CORRESP	Vitae Pharmaceuticals ESP CORRESP 1 filename1.htm Vitae Pharmaceuticals, Inc. 502 West Office Center Drive Fort Washington, PA 19034 November 4, 2015 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street N.E. Washington, D.C. 20549 Attn: Alla Berenshteyn Re: Vitae Pharmaceuticals, Inc. Registration Statement on Form S-3 (File No. 333-207290) Dear Ms. Berenshteyn: Pursuant to Rule 461 un
October 30, 2015	S-3/A	Vitae Pharmaceuticals S-3/A S-3/A 1 a2226306zs-3a.htm S-3/A Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on October 30, 2015. Registration No. 333-207290 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VITAE PHARMACEUTICALS, INC.
October 5, 2015	EX-4.7	VITAE PHARMACEUTICALS, INC. Dated as of [·] EX-4.7 2 a2226153zex-47.htm EX-4.7 Exhibit 4.7 VITAE PHARMACEUTICALS, INC. INDENTURE Dated as of [·] [·] Trustee TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS SECTION 1.01. Certain Terms Defined 1 SECTION 1.02. Other Definitions 5 SECTION 1.03. Rules of Construction 5 ARTICLE 2 SECURITY FORMS SECTION 2.01. Forms Generally 5 SECTION 2.02. Guarantees by Guarantor; Form of Guarantee; Release of Guaran
October 5, 2015	S-3	Vitae Pharmaceuticals S-3 S-3 1 a2226153zs-3.htm S-3 Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on October 5, 2015. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VITAE PHARMACEUTICALS, INC. (Exact name of registrant as s
September 30, 2015	SC 13G/A	VTAE / Vitae Pharmaceuticals, Inc. / Biotechnology Value Fund L P - AMENDMENT NO. 1 TO THE SCHEDULE 13G Passive Investment SC 13G/A 1 sc13ga10742202509302015.htm AMENDMENT NO. 1 TO THE SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Vitae Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par
September 30, 2015	SC 13D/A	VTAE / Vitae Pharmaceuticals, Inc. / NEW ENTERPRISE ASSOCIATES 10 L P - VITAE PHARMACEUTICALS, INC. - AMEND. NO. 2 Activist Investment SC 13D/A 1 vitae-sch13d17857.htm VITAE PHARMACEUTICALS, INC. - AMEND. NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Vitae Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $.0001 par value (Title of Class of Securities) 92847N103 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associate
September 30, 2015	EX-99.1	Vitae Pharmaceuticals Appoints Dr. Karen Bernstein to Board of Directors Charles W. Newhall, III steps down from board EX-99.1 2 a15-204641ex99d1.htm EX-99.1 Exhibit 99.1 Vitae Pharmaceuticals Appoints Dr. Karen Bernstein to Board of Directors Charles W. Newhall, III steps down from board FORT WASHINGTON, PA, September 30, 2015 — Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced the appointment of Karen Bernstein, Ph.D., to its board of directors, effective immediat
September 30, 2015	EX-24	POWER OF ATTORNEY Exhibit 24 POWER OF ATTORNEY The undersigned individual (the ?Reporting Person?) hereby constitutes and appoints each of Arthur Fratamico and Richard Morris, signing singly, with full power of substitution, as the Reporting Person?s true and lawful attorney in fact to: (1) prepare, execute in the Reporting Person?s name and on the Reporting Person?s behalf, and submit to the U.
September 30, 2015	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits 8-K 1 a15-2046418k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2015 VITAE PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36617 04-3567753 (State or Other Jurisdic
September 29, 2015	EX-99.1	Vitae Pharmaceuticals Initiates Second Part of a Phase 1 Multiple Ascending Dose Study of VTP-43742 in Psoriatic Patients Top-line proof-of-concept data in psoriasis patients expected by the end of 2015 Exhibit 99.1 Vitae Pharmaceuticals Initiates Second Part of a Phase 1 Multiple Ascending Dose Study of VTP-43742 in Psoriatic Patients Top-line proof-of-concept data in psoriasis patients expected by the end of 2015 FORT WASHINGTON, PA, September 29, 2015 ? Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that it has initiated the second part of it
September 29, 2015	8-K	Financial Statements and Exhibits, Other Events 8-K 1 a15-1936618k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2015 VITAE PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation
September 18, 2015	SC 13G	VTAE / Vitae Pharmaceuticals, Inc. / Adage Capital Partners GP LLC - ADAGE CAPITAL PARTNERS GP, L.L.C. Passive Investment SC 13G 1 p15-1862sc13g.htm ADAGE CAPITAL PARTNERS GP, L.L.C. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Vitae Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92847N103 (CUSIP Number) September 10, 2015 (Date of Event Which Requires Filing of This S
September 8, 2015	EX-99.1	Vitae Pharmaceuticals Announces Positive Top-Line Results from Initial Phase 1 Study of First-in-Class RORgt Inhibitor VTP-43742 in Autoimmune Disorders · Single ascending doses of VTP-43742 safe and generally well-tolerated, demonstrated once-daily EX-99.1 2 a15-191191ex99d1.htm EX-99.1 Exhibit 99.1 Vitae Pharmaceuticals Announces Positive Top-Line Results from Initial Phase 1 Study of First-in-Class RORgt Inhibitor VTP-43742 in Autoimmune Disorders · Single ascending doses of VTP-43742 safe and generally well-tolerated, demonstrated once-daily pharmacokinetics · Robust ex vivo biomarker response, suppressing pro-inflammatory IL-17A by more
September 8, 2015	8-K	Financial Statements and Exhibits, Other Events 8-K 1 a15-1911918k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2015 VITAE PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36617 04-3567753 (State or Other Jurisdict
August 10, 2015	8-K	Financial Statements and Exhibits, Other Events 8-K 1 a15-1732418k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2015 VITAE PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0
August 10, 2015	EX-99.1	Vitae Pharmaceuticals Announces Initiation of a Phase 1 Multiple Ascending Dose Study of VTP-43742 in Autoimmune Disorders EX-99.1 2 a15-173241ex99d1.htm EX-99.1 Exhibit 99.1 Vitae Pharmaceuticals Announces Initiation of a Phase 1 Multiple Ascending Dose Study of VTP-43742 in Autoimmune Disorders FORT WASHINGTON, PA, August 10, 2015 — Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that it has initiated a Phase 1 multiple ascending dose clinical trial of VTP-43742, it
August 5, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36617 VITAE PHARMACEUTICALS, INC.
August 4, 2015	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a15-1686118k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2015 VITAE PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 00
August 4, 2015	EX-99.1	Vitae Pharmaceuticals Reports Second Quarter 2015 Operating and Financial Results Multiple potential milestones in 2H 2015 Conference call scheduled for 4:30 p.m. EDT today EX-99.1 2 a15-168611ex99d1.htm EX-99.1 Exhibit 99.1 Vitae Pharmaceuticals Reports Second Quarter 2015 Operating and Financial Results Multiple potential milestones in 2H 2015 Conference call scheduled for 4:30 p.m. EDT today FORT WASHINGTON, PA, August 4, 2015 — Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE), a clinical-stage biotechnology company developing a robust and growing portfolio generated by
July 29, 2015	EX-24	POWER OF ATTORNEY Exhibit 24 POWER OF ATTORNEY The undersigned individual (the ?Reporting Person?) hereby constitutes and appoints each of Arthur Fratamico and Richard Morris, signing singly, with full power of substitution, as the Reporting Person?s true and lawful attorney in fact to: (1) prepare, execute in the Reporting Person?s name and on the Reporting Person?s behalf, and submit to the U.
July 29, 2015	EX-99.1	Vitae Pharmaceuticals Appoints Dr. John M. Leonard to Board of Directors EX-99.1 2 a15-165293ex99d1.htm EX-99.1 Exhibit 99.1 Vitae Pharmaceuticals Appoints Dr. John M. Leonard to Board of Directors FORT WASHINGTON, PA, July 29, 2015 — Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced the appointment of John M. Leonard, M.D., to its board of directors, effective immediately. A 30-year biopharmaceutical industry veteran, D
July 29, 2015	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits 8-K 1 a15-1652938k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2015 VITAE PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001
July 27, 2015	EX-99.1	Vitae Pharmaceuticals and Boehringer Ingelheim to End Collaboration and License Agreement for BACE Inhibitors Vitae Expects to Receive Rights to BI-1147560 / VTP-36951 Company to Assess Program to Determine Next Steps Exhibit 99.1 Vitae Pharmaceuticals and Boehringer Ingelheim to End Collaboration and License Agreement for BACE Inhibitors Vitae Expects to Receive Rights to BI-1147560 / VTP-36951 Company to Assess Program to Determine Next Steps FORT WASHINGTON, PA, July 27, 2015 ? Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE), a clinical-stage biotechnology company, today announced that Boehringer Ingelheim (BI) h
July 27, 2015	8-K	Termination of a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2015 VITAE PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36617 (Commission File Num
July 8, 2015	SC 13D/A	VTAE / Vitae Pharmaceuticals, Inc. / NEW ENTERPRISE ASSOCIATES 10 L P - VITAE PHARMACEUTICALS, INC. - AMEND. NO.1 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Vitae Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $.0001 par value (Title of Class of Securities) 92847N103 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600 Timonium, MD 21093 (410) 842-4000 (Name,
June 29, 2015	EX-99.2	Vitae Pharmaceuticals Announces Initiation of a Phase 1 Single Ascending Dose Study of VTP-43742 in Autoimmune Disorders EX-99.2 3 a15-148781ex99d2.htm EX-99.2 Exhibit 99.2 Vitae Pharmaceuticals Announces Initiation of a Phase 1 Single Ascending Dose Study of VTP-43742 in Autoimmune Disorders FORT WASHINGTON, PA, June 29, 2015 — Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE), a clinical-stage biotechnology company, today announced the initiation of a Phase 1 single ascending dose clinical trial of VTP-43742, the Company
June 29, 2015	8-K	Financial Statements and Exhibits, Other Events 8-K 1 a15-1487818k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2015 VITAE PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001
June 29, 2015	EX-99.1	Vitae Pharmaceuticals Announces Top-Line Results from Metformin Arm of Ongoing Phase 2 Clinical Trial of BI187004/VTP-34072 in Overweight Type 2 Diabetics EX-99.1 2 a15-148781ex99d1.htm EX-99.1 Exhibit 99.1 Vitae Pharmaceuticals Announces Top-Line Results from Metformin Arm of Ongoing Phase 2 Clinical Trial of BI187004/VTP-34072 in Overweight Type 2 Diabetics FORT WASHINGTON, PA, June 29, 2015 — Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE), a clinical-stage biotechnology company, today announced top-line clinical efficacy results from the metformin ar
June 1, 2015	S-8	Vitae Pharmaceuticals S-8 S-8 1 a15-131091s8.htm S-8 As filed with the Securities and Exchange Commission on June 1, 2015 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under The Securities Act of 1933 Vitae Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 04-3567753 (State or Other Jurisdiction of Incorporat
May 29, 2015	8-K	Vitae Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2015 VITAE PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36617 04-3567753 (State or Other Jurisdiction of Incorporation) (Commissio
May 12, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 a15-7980110q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-366
May 12, 2015	EX-99.1	Vitae Pharmaceuticals Reports First Quarter 2015 Operating and Financial Results Multiple impending 2Q inflection points supported by enhanced cash position Conference call scheduled for 4:30 p.m. EDT today EX-99.1 2 a15-113481ex99d1.htm EX-99.1 Exhibit 99.1 Vitae Pharmaceuticals Reports First Quarter 2015 Operating and Financial Results Multiple impending 2Q inflection points supported by enhanced cash position Conference call scheduled for 4:30 p.m. EDT today FORT WASHINGTON, PA, May 12, 2015 — Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE), a clinical-stage biotechnology company developing a robust an
May 12, 2015	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 12, 2015 VITAE PHARMACEUTICALS, INC.
April 15, 2015	DEFA14A	Vitae Pharmaceuticals DEFA14A DEFA14A 1 a15-88583defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Comm
April 15, 2015	DEF 14A	Vitae Pharmaceuticals DEF 14A Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 31, 2015	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Use these links to rapidly review the document TABLE OF CONTENTS Vitae Pharmaceuticals, Inc.
March 31, 2015	EX-10.5	VITAE PHARMACEUTICALS, INC. 2014 EQUITY INCENTIVE PLAN (AS ADOPTED ON JULY 23, 2014) Exhibit 10.5 VITAE PHARMACEUTICALS, INC. 2014 EQUITY INCENTIVE PLAN (AS ADOPTED ON JULY 23, 2014) VITAE PHARMACEUTICALS, INC. 2014 EQUITY INCENTIVE PLAN ARTICLE 1. INTRODUCTION. The Board adopted the Plan to become effective immediately, although no Awards may be granted prior to the IPO Date. The purpose of the Plan is to promote the long-term success of the Company and the creation of stockholde
March 31, 2015	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 31, 2015 VITAE PHARMACEUTICALS, INC.
March 31, 2015	EX-99.1	Vitae Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Operating and Financial Results Conference call scheduled for 8:30 a.m. EDT today Exhibit 99.1 Vitae Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Operating and Financial Results Conference call scheduled for 8:30 a.m. EDT today FORT WASHINGTON, PA, March 31, 2015 ? Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE), a clinical-stage biotechnology company, reported today its operating and financial results for the fourth quarter and full year ended December 31, 2014. ?We co
March 20, 2015	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 18, 2015 VITAE PHARMACEUTICALS, INC.
February 26, 2015	EX-99.1	BACE Inhibitor BI 1181181 Voluntarily put on Temporary Clinical Hold for Safety Evaluation Exhibit 99.1 BACE Inhibitor BI 1181181 Voluntarily put on Temporary Clinical Hold for Safety Evaluation FORT WASHINGTON, PA, February 26, 2015 — Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE), a clinical-stage biotechnology company, today announced that its partner Boehringer Ingelheim has voluntarily placed BI 1181181 on a temporary clinical hold, and has notified regulatory agencies of its decision.
February 26, 2015	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): February 26, 2015 VITAE PHARMACEUTICALS, INC.
February 17, 2015	SC 13G	Vitae Pharmaceuticals SCHEDULE 13G (Passive Acquisition of More Than 5% of Shares) sc13g07422vit01232015.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Vitae Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securit
February 17, 2015	EX-99.1	Joint Filing Agreement EX-99.1 2 ex991to13g07422vit01232015.htm JOINT FILING AGREEMENT Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated February 17, 2015 with respect to the shares of Common Stock of Vitae Pharmaceuticals, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursua
February 17, 2015	SC 13G	Vitae Pharmaceuticals SC 13G (Passive Acquisition of More Than 5% of Shares) CUSIP No. 92847N103 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. )* Vitae Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities)
February 17, 2015	SC 13G	VTAE / Vitae Pharmaceuticals, Inc. / PROSPECT VENTURE PARTNERS II LP - SCHEDULE 13G Passive Investment SC 13G 1 t81435sc13g.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b) AND (c) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. )* Vitae Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 92
February 17, 2015	SC 13G/A	VTAE / Vitae Pharmaceuticals, Inc. / Biotechnology Value Fund L P - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment SC 13G/A 1 sc13ga107422vit12312014.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Vitae Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par valu
February 12, 2015	SC 13G	VTAE / Vitae Pharmaceuticals, Inc. / ATLAS VENTURE FUND VI LP - SC 13G Passive Investment SC 13G 1 a15-43461sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Vitae Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 92847N103 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appr
January 28, 2015	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): January 28, 2015 VITAE PHARMACEUTICALS, INC.
January 28, 2015	EX-99.1	Vitae Pharmaceuticals Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Closing of Follow-on Public Offering of Common Stock EX-99.1 2 a15-32351ex99d1.htm EX-99.1 Exhibit 99.1 Vitae Pharmaceuticals Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Closing of Follow-on Public Offering of Common Stock FORT WASHINGTON, PA, JANUARY 28, 2015 — Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE), a clinical stage biotechnology company, today announced the closing of its previously announced underwritten publ
January 23, 2015	424B1	3,000,000 Shares Common Stock $11.90 per share Use these links to rapidly review the document TABLE OF CONTENTS VITAE PHARMACEUTICALS, INC.
January 20, 2015	S-1/A	VTAE / Vitae Pharmaceuticals, Inc. S-1/A - - S-1/A Use these links to rapidly review the document TABLE OF CONTENTS VITAE PHARMACEUTICALS, INC.
January 20, 2015	EX-1.1	[ ] Shares Vitae Pharmaceuticals, Inc. Common Stock UNDERWRITING AGREEMENT EX-1.1 2 a2222684zex-11.htm EX-1.1 Exhibit 1.1 [ ] Shares Vitae Pharmaceuticals, Inc. Common Stock UNDERWRITING AGREEMENT January [ ], 2015 STIFEL, NICOLAUS & COMPANY, INCORPORATED BMO CAPITAL MARKETS CORP. PIPER JAFFRAY & CO. As representatives of the several Underwriters named in Schedule I hereto c/o Stifel, Nicolaus & Company, Incorporated 787 7th Avenue, 11th Floor New York, New York 10019 an
January 15, 2015	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): January 9, 2015 VITAE PHARMACEUTICALS, INC.
January 8, 2015	S-1	VTAE / Vitae Pharmaceuticals, Inc. S-1 - Registration Statement - S-1 Table of Contents As filed with the Securities and Exchange Commission on January 8, 2015 Registration No.
December 23, 2014	EX-99.1	Vitae Pharmaceuticals Added to Russell 2000® and Russell 3000® Indexes Exhibit 99.1 Vitae Pharmaceuticals Added to Russell 2000® and Russell 3000® Indexes FORT WASHINGTON, PA, December 23, 2014 — Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE), a clinical-stage biotechnology company, today announced that it has been added to the Russell 2000® and Russell 3000® indexes, effective as of the close of the market on Friday, December 19, 2014 and as part of the quarterly Initia
December 23, 2014	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): December 23, 2014 VITAE PHARMACEUTICALS, INC.
November 21, 2014	S-8	VTAE / Vitae Pharmaceuticals, Inc. S-8 - - S-8 As filed with the Securities and Exchange Commission on November 21, 2014 Registration No.
November 12, 2014	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 12, 2014 VITAE PHARMACEUTICALS, INC.
November 12, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36617 VITAE PHARMACEUTICALS,
November 12, 2014	EX-99.1	Vitae Pharmaceuticals Reports Third Quarter 2014 Operating and Financial Results Conference call scheduled for 4:30 p.m. EST today Exhibit 99.1 Vitae Pharmaceuticals Reports Third Quarter 2014 Operating and Financial Results Conference call scheduled for 4:30 p.m. EST today FORT WASHINGTON, PA, November 12, 2014 — Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE), a clinical-stage biotechnology company, reported today its operating and financial results for the third quarter ended September 30, 2014. “The successful completion of ou
October 27, 2014	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): October 27, 2014 VITAE PHARMACEUTICALS, INC.
October 27, 2014	EX-99.1	Vitae Pharmaceuticals Announces Exercise of Underwriters’ Option to Purchase Additional Shares of Initial Public Offering Exhibit 99.1 Vitae Pharmaceuticals Announces Exercise of Underwriters’ Option to Purchase Additional Shares of Initial Public Offering FORT WASHINGTON, PA, OCTOBER 27, 2014 — Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE), a clinical stage biotechnology company, today announced that the underwriters of its previously announced initial public offering (IPO) of common stock have exercised in full their
October 23, 2014	EX-99.1	Joint Filing Agreement Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated October 23, 2014 with respect to the shares of Common Stock of Vitae Pharmaceuticals, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) u
October 23, 2014	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): October 23, 2014 VITAE PHARMACEUTICALS, INC.
October 23, 2014	EX-99.1	### Exhibit 99.1 Positive Top-Line Results achieved from Two Phase 1 Clinical Trials of BACE Inhibitor BI1181181/VTP-37948 in Alzheimer’s Disease · BI1181181/VTP-37948 demonstrated greater than 80% reduction of an Alzheimer’s disease biomarker, the cerebral spinal fluid amyloid beta levels · BI1181181/VTP-37948 was safe and generally well-tolerated with a profile supporting once-daily dosing FORT WASH
October 23, 2014	SC 13G	VTAE / Vitae Pharmaceuticals, Inc. / Biotechnology Value Fund L P - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Vitae Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92847N103 (CUSIP Numb
October 10, 2014	SC 13D	VTAE / Vitae Pharmaceuticals, Inc. / VENROCK ASSOCIATES III LP - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* VITAE PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 92847N103 (CUSIP Number) Attention: General Counsel Venrock Associates III, LP Venrock Associates Venrock Entrepreneurs Fund III, L.P. Venro
October 6, 2014	SC 13D	VTAE / Vitae Pharmaceuticals, Inc. / NEW ENTERPRISE ASSOCIATES 10 L P - VITAE PHARMACEUTICALS, INC. Activist Investment SC 13D 1 vitae-sch13d17711.htm VITAE PHARMACEUTICALS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Vitae Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $.0001 par value (Title of Class of Securities) 92847N103 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring
September 29, 2014	EX-99.1	Vitae Pharmaceuticals Announces Closing of Initial Public Offering Exhibit 99.1 Vitae Pharmaceuticals Announces Closing of Initial Public Offering FORT WASHINGTON, PA., Sept. 29, 2014 — Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE), a clinical stage biotechnology company, today announced the closing of its initial public offering of 6,875,000 shares of common stock at an initial public offering price of $8.00 per share. The aggregate net proceeds to Vitae, after und
September 29, 2014	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): September 29, 2014 VITAE PHARMACEUTICALS, INC.
September 29, 2014	EX-3.1	AMENDED AND RESTATED CERTIFICATE OF INCORPORATION VITAE PHARMACEUTICALS, INC. EX-3.1 2 a14-216111ex3d1.htm EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF VITAE PHARMACEUTICALS, INC. Vitae Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows: 1. That the name of the Corporation is Vitae Pharmaceuticals, Inc. The original Certificate of Incorporation of the
September 24, 2014	FWP	VITAE PHARMACEUTICALS, INC. 6,875,000 Shares Common Stock $8.00 per share Update and Supplement to Preliminary Prospectus dated September 23, 2014 Filed Pursuant to Rule 433 of the Securities Act of 1933 Issuer Free Writing Prospectus dated September 24, 2014 Relating to Preliminary Prospectus dated September 23, 2014 Registration No.
September 24, 2014	424B4	6,875,000 Shares Common Stock $8.00 per share Use these links to rapidly review the document TABLE OF CONTENTS VITAE PHARMACEUTICALS, INC.
September 23, 2014	CORRESP	VTAE / Vitae Pharmaceuticals, Inc. CORRESP - - September 23, 2014 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F.
September 23, 2014	CORRESP	VTAE / Vitae Pharmaceuticals, Inc. CORRESP - - VITAE PHARMACEUTICALS, INC. 502 WEST OFFICE CENTER DRIVE FORT WASHINGTON, PA 19034 September 23, 2014 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attention: Russell Mancuso Tom Jones Re: Vitae Pharmaceuticals, Inc. Registration Statement on Form S-1 (File No. 333-198090) Request for Acceleration of Effective Date Dear Mess
September 23, 2014	S-1/A	VTAE / Vitae Pharmaceuticals, Inc. S-1/A - - S-1/A Use these links to rapidly review the document TABLE OF CONTENTS VITAE PHARMACEUTICALS, INC.
September 23, 2014	CORRESP	VTAE / Vitae Pharmaceuticals, Inc. CORRESP - - GUNDERSON DETTMER STOUGH VILLENEUVE FRANKLIN & HACHIGIAN, LLP ONE MARINA PARK DRIVE, SUITE 900 BOSTON, MA 02210 TELEPHONE: (617) 648-9100 FACSIMILE: (617) 648-9199 September 23, 2014 VIA EDGAR AND COURIER U.
September 22, 2014	S-1/A	VTAE / Vitae Pharmaceuticals, Inc. S-1/A - - S-1/A Use these links to rapidly review the document TABLE OF CONTENTS VITAE PHARMACEUTICALS, INC.
September 22, 2014	CORRESP	VTAE / Vitae Pharmaceuticals, Inc. CORRESP - - GUNDERSON DETTMER STOUGH VILLENEUVE FRANKLIN & HACHIGIAN, LLP ONE MARINA PARK DRIVE, SUITE 900 BOSTON, MA 02210 TELEPHONE: (617) 648-9100 FACSIMILE: (617) 648-9199 September 22, 2014 VIA EDGAR AND OVERNIGHT COURIER U.
September 22, 2014	EX-10.6	CONFIDENTIAL TREATMENT REQUESTED EX-10.6 3 a2221442zex-106.htm EX-10.6 Exhibit 10.6 CONFIDENTIAL TREATMENT REQUESTED EXECUTION COPY RESEARCH COLLABORATION AND LICENSE AGREEMENT BETWEEN VITAE PHARMACEUTICALS, INC. AND BOEHRINGER INGELHEIM INTERNATIONAL GMBH Dated as of October 2, 2007 (the “Effective Date”) Boehringer Ingelheim Contract Number: 43015879 CONFIDENTIAL TREATMENT REQUESTED EXECUTION COPY TABLE OF CONTENTS Page 1. DEFI
September 22, 2014	EX-10.10	CONFIDENTIAL TREATMENT REQUESTED BACE RESEARCH COLLABORATION AND LICENSE AGREEMENT BACE RESEARCH COLLABORATION AND LICENSE AGREEMENT VITAE PHARMACEUTICALS, INC. BOEHRINGER INGELHEIM INTERNATIONAL GMBH Dated as of 4th June 2009 Boehringer Ingelheim Co EX-10.10 5 a2221442zex-1010.htm EX-10.10 Exhibit 10.10 CONFIDENTIAL TREATMENT REQUESTED BACE RESEARCH COLLABORATION AND LICENSE AGREEMENT BACE RESEARCH COLLABORATION AND LICENSE AGREEMENT BETWEEN VITAE PHARMACEUTICALS, INC. AND BOEHRINGER INGELHEIM INTERNATIONAL GMBH Dated as of 4th June 2009 Boehringer Ingelheim Contract Number: 43025539 CONFIDENTIAL TREATMENT REQUESTED BACE RESEARCH COLLABORATIO
September 22, 2014	EX-10.8	CONFIDENTIAL TREATMENT REQUESTED AMENDMENT AGREEMENT NO. 2 TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENT Exhibit 10.8 CONFIDENTIAL TREATMENT REQUESTED AMENDMENT AGREEMENT NO. 2 TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENT This Amendment Agreement No. 2 (“Amendment”) is made to the Research Collaboration and License Agreement between Vitae Pharamaceuticals, Inc. (“Vitae”), with offices at 502 West Office Center Drive, Ft. Washington, PA 19034, USA (taxpayer ID number 04-03567753), and Boehringe
September 19, 2014	CORRESP	VTAE / Vitae Pharmaceuticals, Inc. CORRESP - - September 19, 2014 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Jeffrey P. Riedler Russell Mancuso Tom Jones Re: Vitae Pharmaceuticals, Inc. (the “Company”) Registration Statement on Form S-1 (File No. 333-198090) Gentlemen: As representatives of the several underwriters of the Company’s proposed public offering of common stock, we hereby join the Company’s re
September 19, 2014	CORRESP	VTAE / Vitae Pharmaceuticals, Inc. CORRESP - - VITAE PHARMACEUTICALS, INC. 502 WEST OFFICE CENTER DRIVE FORT WASHINGTON, PA 19034 September 19, 2014 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attention: Russell Mancuso Tom Jones Re: Vitae Pharmaceuticals, Inc. Registration Statement on Form S-1 (File No. 333-198090) Request for Acceleration of Effective Date Dear Mess
September 11, 2014	EX-10.6	CONFIDENTIAL TREATMENT REQUESTED EX-10.6 2 a2221384zex-106.htm EX-10.6 Exhibit 10.6 CONFIDENTIAL TREATMENT REQUESTED EXECUTION COPY RESEARCH COLLABORATION AND LICENSE AGREEMENT BETWEEN VITAE PHARMACEUTICALS, INC. AND BOEHRINGER INGELHEIM INTERNATIONAL GMBH Dated as of October 2, 2007 (the “Effective Date”) Boehringer Ingelheim Contract Number: 43015879 CONFIDENTIAL TREATMENT REQUESTED EXECUTION COPY TABLE OF CONTENTS Page 1. DEFI
September 11, 2014	EX-10.10	CONFIDENTIAL TREATMENT REQUESTED BACE RESEARCH COLLABORATION AND LICENSE AGREEMENT BACE RESEARCH COLLABORATION AND LICENSE AGREEMENT VITAE PHARMACEUTICALS, INC. BOEHRINGER INGELHEIM INTERNATIONAL GMBH Dated as of 4th June 2009 Boehringer Ingelheim Co EX-10.10 3 a2221384zex-1010.htm EX-10.10 Exhibit 10.10 CONFIDENTIAL TREATMENT REQUESTED BACE RESEARCH COLLABORATION AND LICENSE AGREEMENT BACE RESEARCH COLLABORATION AND LICENSE AGREEMENT BETWEEN VITAE PHARMACEUTICALS, INC. AND BOEHRINGER INGELHEIM INTERNATIONAL GMBH Dated as of 4th June 2009 Boehringer Ingelheim Contract Number: 43025539 CONFIDENTIAL TREATMENT REQUESTED BACE RESEARCH COLLABORATIO
September 11, 2014	EX-10.12	CONFIDENTIAL TREATMENT REQUESTED AMENDMENT AGREEMENT NO. 2 TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENT Exhibit 10.12 CONFIDENTIAL TREATMENT REQUESTED AMENDMENT AGREEMENT NO. 2 TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENT This Amendment Agreement No. 2 (“Amendment”) is made to the BACE Research Collaboration and License Agreement between Vitae Pharmaceuticals, Inc. (“Vitae”), with offices at 502 West Office Center Drive, Fort Washington, PA 19034, USA (taxpayer ID number 04-03567753), and Boe
September 11, 2014	S-1/A	VTAE / Vitae Pharmaceuticals, Inc. S-1/A - - S-1/A QuickLinks - Click here to rapidly navigate through this document As filed with the Securities and Exchange Commission on September 10, 2014 Registration No.
September 10, 2014	8-A12B	VTAE / Vitae Pharmaceuticals, Inc. 8-A12B - - 8-A12B 8-A12B 1 a14-2037918a12b.htm 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF l934 VITAE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 04-3567753 (State of incorporation or organization) (I.R.S. Employer
September 8, 2014	EX-10.29	VITAE PHARMACEUTICALS, INC. 2014 EMPLOYEE STOCK PURCHASE PLAN (AS ADOPTED PRIOR TO THE INITIAL PUBLIC OFFERING) Exhibit 10.29 VITAE PHARMACEUTICALS, INC. 2014 EMPLOYEE STOCK PURCHASE PLAN (AS ADOPTED PRIOR TO THE INITIAL PUBLIC OFFERING) VITAE PHARMACEUTICALS, INC. 2014 EMPLOYEE STOCK PURCHASE PLAN SECTION 1. PURPOSE OF THE PLAN. The Board adopted the Plan effective as of the IPO Date. The purpose of the Plan is to provide Eligible Employees with an opportunity to increase their proprietary interest in the
September 8, 2014	S-1/A	VTAE / Vitae Pharmaceuticals, Inc. S-1/A - - S-1/A Use these links to rapidly review the document TABLE OF CONTENTS VITAE PHARMACEUTICALS, INC.
September 8, 2014	EX-10.31	Non-Employee Director Compensation Program EX-10.31 10 a2221300zex-1031.htm EX-10.31 Exhibit 10.31 Non-Employee Director Compensation Program Role Element Description Board Member Initial Equity Grant Option to purchase 17,000 shares (as equitably adjusted for any stock splits) of Common Stock granted on the initial date of election of a director (or in the case of a continuing director upon the effective date of the Company’s IPO); Vestin
September 8, 2014	EX-4.1	COUNTERSIGNED: BROADRIDGE CORPORATE ISSUER SOLUTIONS, INC. 1717 ARCH ST., STE. 1300, PHILADELPHIA, PA 19103 TRANSFER AGENT BY: AUTHORIZED SIGNATURE NUMBER SHARES DATED: THIS CERTIFIES THAT: IS THE OWNER OF SPECIMEN SPECIMEN SPECIMEN INCORPORATED UNDE Exhibit 4.1 COUNTERSIGNED: BROADRIDGE CORPORATE ISSUER SOLUTIONS, INC. 1717 ARCH ST., STE. 1300, PHILADELPHIA, PA 19103 TRANSFER AGENT BY: AUTHORIZED SIGNATURE NUMBER SHARES DATED: THIS CERTIFIES THAT: IS THE OWNER OF SPECIMEN SPECIMEN SPECIMEN INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE transferable on the books of the Corporation by the holder thereof in person or by duly authorized att
September 8, 2014	EX-1.1	[Number of Firm Shares] Shares Vitae Pharmaceuticals, Inc. Common Stock UNDERWRITING AGREEMENT EX-1.1 2 a2221300zex-11.htm EX-1.1 Exhibit 1.1 [Number of Firm Shares] Shares Vitae Pharmaceuticals, Inc. Common Stock UNDERWRITING AGREEMENT [ ], 2014 STIFEL, NICOLAUS & COMPANY, INCORPORATED BMO CAPITAL MARKETS CORP. As representatives of the several Underwriters named in Schedule I hereto c/o Stifel, Nicolaus & Company, Incorporated 787 7th Avenue, 11th Floor New York, New York 10019 and c/o BM
September 8, 2014	EX-10.5	VITAE PHARMACEUTICALS, INC. 2014 EQUITY INCENTIVE PLAN (AS ADOPTED ON JULY 23, 2014) EX-10.5 7 a2221300zex-105.htm EX-10.5 Exhibit 10.5 VITAE PHARMACEUTICALS, INC. 2014 EQUITY INCENTIVE PLAN (AS ADOPTED ON JULY 23, 2014) VITAE PHARMACEUTICALS, INC. 2014 EQUITY INCENTIVE PLAN ARTICLE 1. INTRODUCTION. The Board adopted the Plan to become effective immediately, although no Awards may be granted prior to the IPO Date. The purpose of the Plan is to promote the long-term success of the
September 8, 2014	EX-10.30	VITAE PHARMACEUTICALS, INC. MANAGEMENT CASH INCENTIVE PLAN (AS ADOPTED EFFECTIVE JULY 23, 2014) EX-10.30 9 a2221300zex-1030.htm EX-10.30 Exhibit 10.30 VITAE PHARMACEUTICALS, INC. MANAGEMENT CASH INCENTIVE PLAN (AS ADOPTED EFFECTIVE JULY 23, 2014) TABLE OF CONTENTS Page ARTICLE 1. BACKGROUND AND PURPOSE 1 1.1 Effective Date 1 1.2 Purpose of the Plan 1 ARTICLE 2. DEFINITIONS 1 ARTICLE 3. SELECTION OF PARTICIPANTS AND DETERMINATION OF AWARDS 3 3.1 Selection of Participants 3 3.2 Determination o
September 8, 2014	EX-3.2	AMENDED AND RESTATED CERTIFICATE OF INCORPORATION VITAE PHARMACEUTICALS, INC. EX-3.2 4 a2221300zex-32.htm EX-3.2 Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF VITAE PHARMACEUTICALS, INC. Vitae Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows: 1. This Amended and Restated Certificate of Incorporation, which restates, integrates and further amends the certifi
September 8, 2014	CORRESP	VTAE / Vitae Pharmaceuticals, Inc. CORRESP - - CORRESP 1 filename1.htm GUNDERSON DETTMER STOUGH VILLENEUVE FRANKLIN & HACHIGIAN, LLP ONE MARINA PARK DRIVE, SUITE 900 BOSTON, MA 02210 TELEPHONE: (617) 648-9100 FACSIMILE: (617) 648-9199 September 8, 2014 VIA EDGAR AND OVERNIGHT COURIER Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attention: Russell Mancuso Tom Jones Re: Vitae Pharm
September 8, 2014	EX-3.1	The First State EX-3.1 3 a2221300zex-31.htm EX-3.1 Exhibit 3.1 Delaware The First State I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED ARE TRUE AND CORRECT COPIES OF ALL DOCUMENTS ON FILE OF “VITAE PHARMACEUTICALS, INC.” AS RECEIVED AND FILED IN THIS OFFICE. THE FOLLOWING DOCUMENTS HAVE BEEN CERTIFIED: CERTIFICATE OF INCORPORATION, FILED THE TWENTY-FIRST DAY OF
September 8, 2014	CORRESP	VTAE / Vitae Pharmaceuticals, Inc. CORRESP - - CORRESP 1 filename1.htm GUNDERSON DETTMER STOUGH VILLENEUVE FRANKLIN & HACHIGIAN, LLP ONE MARINA PARK DRIVE, SUITE 900 BOSTON, MA 02210 TELEPHONE: (617) 648-9100 FACSIMILE: (617) 648-9199 September 8, 2014 VIA EDGAR AND OVERNIGHT COURIER Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attention: Russell Mancuso Tom Jones Re: Vitae Pharm
August 29, 2014	EX-10.12	CONFIDENTIAL TREATMENT REQUESTED AMENDMENT AGREEMENT NO. 2 TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENT Exhibit 10.12 CONFIDENTIAL TREATMENT REQUESTED AMENDMENT AGREEMENT NO. 2 TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENT This Amendment Agreement No. 2 (“Amendment”) is made to the BACE Research Collaboration and License Agreement between Vitae Pharmaceuticals, Inc. (“Vitae”), with offices at 502 West Office Center Drive, Fort Washington, PA 19034, USA (taxpayer ID number 04-03567753), and Boe
August 29, 2014	EX-10.13	CONFIDENTIAL TREATMENT REQUESTED AMENDMENT AGREEMENT NO. 3 TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENT Exhibit 10.13 CONFIDENTIAL TREATMENT REQUESTED AMENDMENT AGREEMENT NO. 3 TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENT This Amendment Agreement No. 3 (“Amendment 3”) is made to the BACE Research Collaboration and License Agreement between Vitae Pharmaceuticals, Inc. (“Vitae”), with offices at 502 West Office Center Drive, Fort Washington, PA 19034, USA (taxpayer ID number 04-03567753), and B
August 29, 2014	EX-10.11	CONFIDENTIAL TREATMENT REQUESTED Amendment No. 1 Exhibit 10.11 CONFIDENTIAL TREATMENT REQUESTED Amendment No. 1 to BACE Research Collaboration and License Agreement between Vitae Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH, dated June 4, 2009 (the “Agreement”). This Amendment No. 1 to the Agreement sets forth the mutual understanding concerning modifications of this Agreement. Capitalized terms used in this 1st Amendment a
August 29, 2014	EX-10.7	AMENDMENT AGREEMENT TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENT EX-10.7 3 a2221275zex-107.htm EX-10.7 Exhibit 10.7 AMENDMENT AGREEMENT TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENT This AMENDMENT AGREEMENT TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENT (“Amendment Agreement”), effective as of October 8, 2007, is entered into by and between Vitae Pharmaceuticals, Inc (“Vitae”), with offices at 502 West Office Center Drive, Ft. Washington, PA 19034, U
August 29, 2014	EX-10.9	AMENDMENT AGREEMENT NO. 3 TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENT EX-10.9 5 a2221275zex-109.htm EX-10.9 Exhibit 10.9 AMENDMENT AGREEMENT NO. 3 TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENT This Amendment Agreement No. 3 (“Amendment”) is made to the Research Collaboration and License Agreement between Vitae Pharmaceuticals, Inc. (“Vitae”), with offices at 502 West Office Center Drive, Ft. Washington, PA 19034, USA (taxpayer ID number 04- 03567753), and Boeh
August 29, 2014	EX-10.8	CONFIDENTIAL TREATMENT REQUESTED AMENDMENT AGREEMENT NO. 2 TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENT EX-10.8 4 a2221275zex-108.htm EX-10.8 Exhibit 10.8 CONFIDENTIAL TREATMENT REQUESTED AMENDMENT AGREEMENT NO. 2 TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENT This Amendment Agreement No. 2 (“Amendment”) is made to the Research Collaboration and License Agreement between Vitae Pharamaceuticals, Inc. (“Vitae”), with offices at 502 West Office Center Drive, Ft. Washington, PA 19034, USA (taxpayer
August 29, 2014	EX-10.10	CONFIDENTIAL TREATMENT REQUESTED BACE RESEARCH COLLABORATION AND LICENSE AGREEMENT BACE RESEARCH COLLABORATION AND LICENSE AGREEMENT VITAE PHARMACEUTICALS, INC. BOEHRINGER INGELHEIM INTERNATIONAL GMBH Dated as of 4th June 2009 Boehringer Ingelheim Co EX-10.10 6 a2221275zex-1010.htm EX-10.10 Exhibit 10.10 CONFIDENTIAL TREATMENT REQUESTED BACE RESEARCH COLLABORATION AND LICENSE AGREEMENT BACE RESEARCH COLLABORATION AND LICENSE AGREEMENT BETWEEN VITAE PHARMACEUTICALS, INC. AND BOEHRINGER INGELHEIM INTERNATIONAL GMBH Dated as of 4th June 2009 Boehringer Ingelheim Contract Number: 43025539 CONFIDENTIAL TREATMENT REQUESTED BACE RESEARCH COLLABORATIO
August 29, 2014	S-1/A	VTAE / Vitae Pharmaceuticals, Inc. S-1/A - - S-1/A QuickLinks - Click here to rapidly navigate through this document As filed with the Securities and Exchange Commission on August 28, 2014 Registration No.
August 29, 2014	EX-10.6	CONFIDENTIAL TREATMENT REQUESTED Exhibit 10.6 CONFIDENTIAL TREATMENT REQUESTED EXECUTION COPY RESEARCH COLLABORATION AND LICENSE AGREEMENT BETWEEN VITAE PHARMACEUTICALS, INC. AND BOEHRINGER INGELHEIM INTERNATIONAL GMBH Dated as of October 2, 2007 (the “Effective Date”) Boehringer Ingelheim Contract Number: 43015879 CONFIDENTIAL TREATMENT REQUESTED EXECUTION COPY TABLE OF CONTENTS Page 1. DEFINITIONS 1 2. LICENSE GRANTS, OWNERSHIP
August 28, 2014	EX-10.24	LOAN AND SECURITY AGREEMENT EX-10.24 3 a2221229zex-1024.htm EX-10.24 Exhibit 10.24 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of December 22, 2011 (the “Effective Date”) among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (the “Collateral Agent”), and the Lend
August 28, 2014	CORRESP	VTAE / Vitae Pharmaceuticals, Inc. CORRESP - - CORRESP 1 filename1.htm August 28, 2014 CONFIDENTIAL TREATMENT REQUESTED BY VITAE PHARMACEUTICALS, INC. PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND, WHERE APPLICABLE, HAVE BEEN MARKED WITH AN ASTERISK TO DENOTE WHERE OMISSIONS HAVE BEEN MADE. THE CONFIDENTIAL MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Via EDG
August 28, 2014	EX-10.2	VITAE PHARMACEUTICALS, INC. 2001 STOCK PLAN ADOPTED ON DECEMBER 10, 2001 LAST AMENDED AND RESTATED ON JULY 25, 2007 EX-10.2 2 a2221229zex-102.htm EX-10.2 Exhibit 10.2 VITAE PHARMACEUTICALS, INC. 2001 STOCK PLAN ADOPTED ON DECEMBER 10, 2001 LAST AMENDED AND RESTATED ON JULY 25, 2007 TABLE OF CONTENTS Page SECTION 1. Establishment and Purpose 1 SECTION 2. Administration 1 (a) Committees of the Board of Directors 1 (b) Authority of the Board of Directors 1 SECTION 3. Eligibility 1 (a) General Rule 1 (b) Ten-Percen
August 28, 2014	S-1/A	VTAE / Vitae Pharmaceuticals, Inc. S-1/A - - S-1/A Use these links to rapidly review the document TABLE OF CONTENTS VITAE PHARMACEUTICALS, INC.
August 27, 2014	CORRESP	VTAE / Vitae Pharmaceuticals, Inc. CORRESP - - CORRESP 1 filename1.htm GUNDERSON DETTMER STOUGH VILLENEUVE FRANKLIN & HACHIGIAN, LLP ONE MARINA PARK DRIVE, SUITE 900 BOSTON, MA 02210 TELEPHONE: (617) 648-9100 FACSIMILE: (617) 648-9199 August 27, 2014 VIA EDGAR AND OVERNIGHT COURIER Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attention: Russell Mancuso Tom Jones Re: Vitae Pharmac
August 12, 2014	EX-10.25	WARRANT TO PURCHASE STOCK EX-10.25 29 a2221051zex-1025.htm EX-10.25 Exhibit 10.25 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE
August 12, 2014	EX-10.24	LOAN AND SECURITY AGREEMENT EX-10.24 28 a2221051zex-1024.htm EX-10.24 Exhibit 10.24 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of December 22, 2011 (the “Effective Date”) among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (the “Collateral Agent”), and the Len
August 12, 2014	EX-10.2	VITAE PHARMACEUTICALS, INC. 2001 STOCK PLAN ADOPTED ON DECEMBER 10, 2001 LAST AMENDED AND RESTATED ON JULY 25, 2007 EX-10.2 7 a2221051zex-102.htm EX-10.2 Exhibit 10.2 VITAE PHARMACEUTICALS, INC. 2001 STOCK PLAN ADOPTED ON DECEMBER 10, 2001 LAST AMENDED AND RESTATED ON JULY 25, 2007 TABLE OF CONTENTS Page SECTION 1. Establishment and Purpose 1 SECTION 2. Administration 1 (a) Committees of the Board of Directors 1 (b) Authority of the Board of Directors 1 SECTION 3. Eligibility 1 (a) General Rule 1 (b) Ten-Percen
August 12, 2014	EX-10.23	Vitae Pharmaceuticals, Inc. 502 West Office Center Drive Ft. Washington, PA 19034 April 3, 2006 EX-10.23 27 a2221051zex-1023.htm EX-10.23 Exhibit 10.23 Vitae Pharmaceuticals, Inc. 502 West Office Center Drive Ft. Washington, PA 19034 April 3, 2006 Donald J. Hayden, Jr. Dear Donald, Vitae Pharmaceuticals, Inc. (the “Company”) is pleased to offer you a position as Chairman of the Company’s Board of Directors (the “Board”). The following letter agreement sets forth our agreement regarding the t
August 12, 2014	EX-10.27	WARRANT TO PURCHASE STOCK Exhibit 10.27 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBST
August 12, 2014	EX-10.4	VITAE PHARMACEUTICALS, INC. 2013 STOCK PLAN ADOPTED ON NOVEMBER 20, 2013 Exhibit 10.4 VITAE PHARMACEUTICALS, INC. 2013 STOCK PLAN ADOPTED ON NOVEMBER 20, 2013 TABLE OF CONTENTS Page SECTION 1. ESTABLISHMENT AND PURPOSE 1 SECTION 2. ADMINISTRATION 1 (a) Committees of the Board of Directors 1 (b) Authority of the Board of Directors 1 SECTION 3. ELIGIBILITY 1 (a) General Rule 1 (b) Ten-Percent Stockholders 2 SECTION 4. STOCK SUBJECT TO PLAN 2 (a) Basic Limitation 2 (b) Ad
August 12, 2014	EX-10.20	2 EX-10.20 24 a2221051zex-1020.htm EX-10.20 Exhibit 10.20 502 West Office Center Drive Fort Washington, PA 19034 Phone: 215.461.2000 Fax: 215.461.2006 www.vitaepharma.com July 21, 2008 Tina Fiumencro Dear Tina: You and Vitae Pharmaceuticals, Inc. (the “Company”) signed an offer letter dated December 19, 2005 (the “Offer Letter”). To avoid potential adverse tax consequences imposed by Section 409A of
August 12, 2014	EX-10.11	CONFIDENTIAL TREATMENT REQUESTED Amendment No. 1 Exhibit 10.11 CONFIDENTIAL TREATMENT REQUESTED Amendment No. 1 to BACE Research Collaboration and License Agreement between Vitae Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH, dated June 4, 2009 (the “Agreement”). This Amendment No. 1 to the Agreement sets forth the mutual understanding concerning modifications of this Agreement. Capitalized terms used in this 1st Amendment a
August 12, 2014	EX-10.14	435 TASSO STREET, SUITE 200 · PALO ALTO, CALIFORNIA 94301 PHONE (650) 327-8800 FAX (650) 324-8838 EX-10.14 18 a2221051zex-1014.htm EX-10.14 Exhibit 10.14 Prospect Venture Partners February 25, 2004 HIGHLY CONFIDENTIAL TO BE READ BY ADDRESSEE ONLY Mr. Jeffrey Hatfield Dear Jeff: As you are no doubt aware, all of us have greatly enjoyed our interactions with you and have developed a deep respect for your talents. As such we are delighted to convey this offer to join Concurrent Pharmaceuticals as
August 12, 2014	EX-10.16	502 West Office Center Drive Fort Washington, PA 19034 Phone: 215.461.2000 Fax: 215.461.2006 www.vitaepharma.com EX-10.16 20 a2221051zex-1016.htm EX-10.16 Exhibit 10.16 502 West Office Center Drive Fort Washington, PA 19034 Phone: 215.461.2000 Fax: 215.461.2006 www.vitaepharma.com September 4, 2013 Jeffrey Hatfield Dear Jeff: This letter amends your original Offer Letter dated February 25, 2004 as it pertains to your annual performance bonus. As approved by the Board of Directors, you will be eligible for an
August 12, 2014	EX-10.21	May 7, 2014 Exhibit 10.21 502 West Office Center Drive Fort Washington, PA 19034 Phone: 215.461.2000 Fax: 215.461.2006 www.vitaepharma.com May 7, 2014 Arthur J. Fratamico, R.Ph., MBA Dear Art: On behalf of Vitae Pharmaceuticals, Inc. (the “Company”), I am pleased to offer you the position of Chief Business Officer reporting directly to me. The terms of this employment offer are as follows: Effective Date: The
August 12, 2014	EX-10.3	CONCURRENT PHARMACEUTICALS, INC. 2004 STOCK PLAN ADOPTED ON MAY , 2004 Exhibit 10.3 CONCURRENT PHARMACEUTICALS, INC. 2004 STOCK PLAN ADOPTED ON MAY , 2004 TABLE OF CONTENTS Page No. SECTION 1. ESTABLISHMENT AND PURPOSE 1 SECTION 2. ADMINISTRATION 1 (a) Committees of the Board of Directors 1 (b) Authority of the Board of Directors 1 SECTION 3. ELIGIBILITY 1 (a) General Rule 1 (b) Ten-Percent Stockholders 1 SECTION 4. STOCK SUBJECT TO PLAN 2 (a) Basic Limitation 2 (b)
August 12, 2014	EX-3.1	The First State EX-3.1 2 a2221051zex-31.htm EX-3.1 Exhibit 3.1 Delaware The First State I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED ARE TRUE AND CORRECT COPIES OF ALL DOCUMENTS ON FILE OF “VITAE PHARMACEUTICALS, INC.” AS RECEIVED AND FILED IN THIS OFFICE. THE FOLLOWING DOCUMENTS HAVE BEEN CERTIFIED: CERTIFICATE OF INCORPORATION, FILED THE TWENTY-FIRST DAY OF
August 12, 2014	EX-4.2	VITAE PHARMACEUTICALS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT OCTOBER 2, 2007 EX-4.2 5 a2221051zex-42.htm EX-4.2 Exhibit 4.2 VITAE PHARMACEUTICALS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT OCTOBER 2, 2007 TABLE OF CONTENTS Page 1. Registration Rights 2 1.1 Definitions 2 1.2 Request for Registration 3 1.3 Company Registration 4 1.4 Form S-3 Registration 5 1.5 Obligations of the Company 6 1.6 Information from Holder 7 1.7 Expenses of Registration 7 1.8 Delay of R
August 12, 2014	S-1	VTAE / Vitae Pharmaceuticals, Inc. S-1 - Registration Statement - S-1 S-1 1 a2221051zs-1.htm S-1 Use these links to rapidly review the document TABLE OF CONTENTS VITAE PHARMACEUTICALS, INC. Index to Financial Statements As filed with the Securities and Exchange Commission on August 12, 2014 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VITAE PHARMACEUTICA
August 12, 2014	EX-10.7	CONFIDENTIAL TREATMENT REQUESTED AMENDMENT AGREEMENT TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENT EX-10.7 11 a2221051zex-107.htm EX-10.7 Exhibit 10.7 CONFIDENTIAL TREATMENT REQUESTED AMENDMENT AGREEMENT TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENT This AMENDMENT AGREEMENT TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENT (“Amendment Agreement”), effective as of October 8, 2007, is entered into by and between Vitae Pharmaceuticals, Inc (“Vitae”), with offices at 502 West Office Center
August 12, 2014	EX-10.6	CONFIDENTIAL TREATMENT REQUESTED RESEARCH COLLABORATION AND LICENSE AGREEMENT VITAE PHARMACEUTICALS, INC. BOEHRINGER INGELHEIM INTERNATIONAL GMBH Dated as of October 2, 2007 (the “Effective Date”) Boehringer Ingelheim Contract Number: ** EX-10.6 10 a2221051zex-106.htm EX-10.6 Exhibit 10.6 CONFIDENTIAL TREATMENT REQUESTED RESEARCH COLLABORATION AND LICENSE AGREEMENT BETWEEN VITAE PHARMACEUTICALS, INC. AND BOEHRINGER INGELHEIM INTERNATIONAL GMBH Dated as of October 2, 2007 (the “Effective Date”) Boehringer Ingelheim Contract Number: **CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL
August 12, 2014	EX-10.19	Tina Fiumenero EX-10.19 23 a2221051zex-1019.htm EX-10.19 Exhibit 10.19 502 West Office Center Drive Fort Washington, PA 19034 Phone: 215.461.2000 Fax: 215.461.2006 www.vitaepharma.com Tina Fiumenero Jeffrey S. Hatfield Chief Executive Officer December 19, 2005 Dear Tina, On behalf of Vitae Pharmaceuticals, Inc. (the “Company”) and the Board of Directors, we are pleased to offer you the position of Senior Vice Pr
August 12, 2014	EX-10.18	502 West Office Center Drive Fort Washington, PA 19034 Phone: 215.461.2000 Fax: 215.461.2006 www.vitaepharma.com EX-10.18 22 a2221051zex-1018.htm EX-10.18 Exhibit 10.18 502 West Office Center Drive Fort Washington, PA 19034 Phone: 215.461.2000 Fax: 215.461.2006 www.vitaepharma.com July 21, 2008 Richard E. Gregg, MD Dear Dick: You and Vitae Pharmaceuticals, Inc. (the “Company”) signed an offer letter dated January 28, 2008 (the “Offer Letter”). To avoid potential adverse tax consequences imposed by Section 40
August 12, 2014	EX-10.15	502 West Office Center Drive Fort Washington, PA 19034 Phone: 215.461.2000 Fax: 215.461.2006 www.vitaepharma.com EX-10.15 19 a2221051zex-1015.htm EX-10.15 Exhibit 10.15 502 West Office Center Drive Fort Washington, PA 19034 Phone: 215.461.2000 Fax: 215.461.2006 www.vitaepharma.com July 21, 2008 Mr. Jeffrey Hatfield Dear Jeff: You and Vitae Pharmaceuticals, Inc. (the “Company”) signed an offer letter dated February 25, 2004 (the “Offer Letter”), To avoid potential adverse tax consequences imposed by Section 4
August 12, 2014	EX-10.1	INDEMNITY AGREEMENT EX-10.1 6 a2221051zex-101.htm EX-10.1 Exhibit 10.1 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of [ ], 20 , is made by and between Vitae Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). RECITALS: A. The Company desires to attract and retain the services of highly qualified individuals as directors, officers, employees and agents. B. Th
August 12, 2014	EX-3.3	BYLAWS OF VITAE PHARMACEUTICALS, INC. (f/k/a CONCURRENT PHARMACEUTICALS, INC.) (A DELAWARE CORPORATION) Exhibit 3.3 BYLAWS OF VITAE PHARMACEUTICALS, INC. (f/k/a CONCURRENT PHARMACEUTICALS, INC.) (A DELAWARE CORPORATION) TABLE OF CONTENTS Page ARTICLE I. OFFICES 1 ARTICLE II. MEETINGS OF STOCKHOLDERS 1 ARTICLE III. DIRECTORS 3 ARTICLE IV. NOTICES 6 ARTICLE V. OFFICERS 7 ARTICLE VI. CERTIFICATE OF STOCK 9 ARTICLE VII. GENERAL PROVISIONS 11 ARTICLE VIII. AMENDMENTS 13 ARTICLE IX. LOANS TO OFFICERS 13 B
August 12, 2014	EX-10.9	CONFIDENTIAL TREATMENT REQUESTED AMENDMENT AGREEMENT NO. 3 TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENT EX-10.9 13 a2221051zex-109.htm EX-10.9 Exhibit 10.9 CONFIDENTIAL TREATMENT REQUESTED AMENDMENT AGREEMENT NO. 3 TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENT This Amendment Agreement No. 3 (“Amendment”) is made to the Research Collaboration and License Agreement between Vitae Pharmaceuticals, Inc. (“Vitae”), with offices at 502 West Office Center Drive, Ft. Washington, PA 19034, USA (taxpayer
August 12, 2014	EX-10.22	May 15, 2014 EX-10.22 26 a2221051zex-1022.htm EX-10.22 Exhibit 10.22 502 West Office Center Drive Fort Washington, PA 19034 Phone: 215.461.2000 Fax: 215.461.2006 www.vitaepharma.com May 15, 2014 Richard Morris Dear Rich: On behalf of Vitae Pharmaceuticals, Inc. (the “Company”), I am pleased to offer you the position of Chief Financial Officer reporting directly to me. The terms of this employment offer are as
August 12, 2014	EX-10.8	CONFIDENTIAL TREATMENT REQUESTED AMENDMENT AGREEMENT NO. 2 TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENT Exhibit 10.8 CONFIDENTIAL TREATMENT REQUESTED AMENDMENT AGREEMENT NO. 2 TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENT This Amendment Agreement No. 2 (“Amendment”) is made to the Research Collaboration and License Agreement between Vitae Pharamaceuticals, Inc. (“Vitae”), with offices at 502 West Office Center Drive, Ft. Washington, PA 19034, USA (taxpayer ID number 04-03567753), and Boehringe
August 12, 2014	EX-10.12	CONFIDENTIAL TREATMENT REQUESTED AMENDMENT AGREEMENT NO. 2 TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENT EX-10.12 16 a2221051zex-1012.htm EX-10.12 Exhibit 10.12 CONFIDENTIAL TREATMENT REQUESTED AMENDMENT AGREEMENT NO. 2 TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENT This Amendment Agreement No. 2 (“Amendment”) is made to the BACE Research Collaboration and License Agreement between Vitae Pharmaceuticals, Inc. (“Vitae”), with offices at 502 West Office Center Drive, Fort Washington, PA 19034, USA
August 12, 2014	EX-10.10	CONFIDENTIAL TREATMENT REQUESTED BACE RESEARCH COLLABORATION AND LICENSE AGREEMENT VITAE PHARMACEUTICALS, INC. BOEHRINGER INGELHEIM INTERNATIONAL GMBH Dated as of 4th June 2009 Boehringer Ingelheim Contract Number: ** EX-10.10 14 a2221051zex-1010.htm EX-10.10 Exhibit 10.10 CONFIDENTIAL TREATMENT REQUESTED BACE RESEARCH COLLABORATION AND LICENSE AGREEMENT BETWEEN VITAE PHARMACEUTICALS, INC. AND BOEHRINGER INGELHEIM INTERNATIONAL GMBH Dated as of 4th June 2009 Boehringer Ingelheim Contract Number: **CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BE
August 12, 2014	EX-10.26	WARRANT TO PURCHASE STOCK Exhibit 10.26 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBST
August 12, 2014	EX-10.13	CONFIDENTIAL TREATMENT REQUESTED AMENDMENT AGREEMENT NO. 3 TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENT EX-10.13 17 a2221051zex-1013.htm EX-10.13 Exhibit 10.13 CONFIDENTIAL TREATMENT REQUESTED AMENDMENT AGREEMENT NO. 3 TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENT This Amendment Agreement No. 3 (“Amendment 3”) is made to the BACE Research Collaboration and License Agreement between Vitae Pharmaceuticals, Inc. (“Vitae”), with offices at 502 West Office Center Drive, Fort Washington, PA 19034, U
August 12, 2014	EX-10.28	AGREEMENT OF LEASE 502 WOC PROPERTIES, LP AS LANDLORD CONCURRENT PHARMACEUTICALS, INC. AS TENANT Exhibit 10.28 AGREEMENT OF LEASE BETWEEN 502 WOC PROPERTIES, LP AS LANDLORD AND CONCURRENT PHARMACEUTICALS, INC. AS TENANT AGREEMENT OF LEASE THIS AGREEMENT OF LEASE made this 11th day of July, 2002 by and between 502 WOC PROPERTIES, LP, a Pennsylvania limited partnership (hereinafter called “Landlord”), and CONCURRENT PHARMACEUTICALS, INC., a Delaware corporation (hereinafter called “Tenant”). 1.
August 12, 2014	EX-3.4	AMENDED AND RESTATED BYLAWS VITAE PHARMACEUTICALS, INC. (as amended on , 2014, effective as of the closing of the corporation’s initial public offering) EX-3.4 4 a2221051zex-34.htm EX-3.4 Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF VITAE PHARMACEUTICALS, INC. (as amended on , 2014, effective as of the closing of the corporation’s initial public offering) TABLE OF CONTENTS Page Article I STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Notice of Meetings 1 1.5 Voting List 2 1.6 Quorum 2 1.7 Adjournments 2 1.8 Vo
August 12, 2014	EX-10.17	502 West Office Center Drive Fort Washington, PA 19034 Phone: 215.461.2000 Fax: 215.461.2006 www.vitaepharma.com Jeffrey S. Hatfield Chief Executive Officer Exhibit 10.17 502 West Office Center Drive Fort Washington, PA 19034 Phone: 215.461.2000 Fax: 215.461.2006 www.vitaepharma.com Jeffrey S. Hatfield Chief Executive Officer January 28, 2008 Richard E. Gregg, MD Dear Dick: I am delighted to confirm my verbal offer to you to join Vitae Pharmaceuticals as our Chief Scientific Officer, reporting directly to me. It is an exciting time to lead the R&D eff
August 5, 2014	EX-10.28	AGREEMENT OF LEASE 502 WOC PROPERTIES, LP AS LANDLORD CONCURRENT PHARMACEUTICALS, INC. AS TENANT EX-10.28 4 filename4.htm Exhibit 10.28 AGREEMENT OF LEASE BETWEEN 502 WOC PROPERTIES, LP AS LANDLORD AND CONCURRENT PHARMACEUTICALS, INC. AS TENANT AGREEMENT OF LEASE THIS AGREEMENT OF LEASE made this 11th day of July, 2002 by and between 502 WOC PROPERTIES, LP, a Pennsylvania limited partnership (hereinafter called “Landlord”), and CONCURRENT PHARMACEUTICALS, INC., a Delaware corporation (hereina
August 5, 2014	DRS/A	VTAE / Vitae Pharmaceuticals, Inc. DRS/A - - Use these links to rapidly review the document TABLE OF CONTENTS VITAE PHARMACEUTICALS, INC.
August 5, 2014	EX-3.4	AMENDED AND RESTATED BYLAWS VITAE PHARMACEUTICALS, INC. (as amended on , 2014, effective as of the closing of the corporation’s initial public offering) EX-3.4 2 filename2.htm Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF VITAE PHARMACEUTICALS, INC. (as amended on , 2014, effective as of the closing of the corporation’s initial public offering) TABLE OF CONTENTS Page Article I STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Notice of Meetings 1 1.5 Voting List 2 1.6 Quorum 2 1.7 Adjournments 2 1.8 Voting and Pro
August 5, 2014	EX-10.1	INDEMNITY AGREEMENT EX-10.1 3 filename3.htm Exhibit 10.1 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of [ ], 20 , is made by and between Vitae Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). RECITALS: A. The Company desires to attract and retain the services of highly qualified individuals as directors, officers, employees and agents. B. The Company’s by

VTAE / Vitae Pharmaceuticals, Inc. - Depositi SEC, Relazione annuale, dichiarazione di delega

Statistiche di base

SEC Filings

SEC Filings (Chronological Order)